Randomized Study to Compare the Bioavailability of Two Clobetasol Propionate 0.05% Topical Foams

NCT ID: NCT00803439

Last Updated: 2021-10-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-04-30

Study Completion Date

2005-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to compare the relative vasoconstrictive effects of test and reference Clobetasol Propionate 0.05% Topical Foam in healthy, female subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort Group 1

Subjects number 1 to 20

Clobetasol Propionate 0.05% Foam-Reference Product

Intervention Type DRUG

Small amount applied and evaluated over the course of two days

Clobetasol Propionate 0.05% Foam-Test product

Intervention Type DRUG

Small amount applied and evaluated over the course of two days

Cohort Group 2

Subjects number 21 to 40

Clobetasol Propionate 0.05% Foam-Reference Product

Intervention Type DRUG

Small amount applied and evaluated over the course of two days

Clobetasol Propionate 0.05% Foam-Test product

Intervention Type DRUG

Small amount applied and evaluated over the course of two days

Cohort Group 3

Subjects number 41 to 60

Clobetasol Propionate 0.05% Foam-Reference Product

Intervention Type DRUG

Small amount applied and evaluated over the course of two days

Clobetasol Propionate 0.05% Foam-Test product

Intervention Type DRUG

Small amount applied and evaluated over the course of two days

Cohort Group 4

Subjects number 61 to 80

Clobetasol Propionate 0.05% Foam-Reference Product

Intervention Type DRUG

Small amount applied and evaluated over the course of two days

Clobetasol Propionate 0.05% Foam-Test product

Intervention Type DRUG

Small amount applied and evaluated over the course of two days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clobetasol Propionate 0.05% Foam-Reference Product

Small amount applied and evaluated over the course of two days

Intervention Type DRUG

Clobetasol Propionate 0.05% Foam-Test product

Small amount applied and evaluated over the course of two days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-tobacco using female subjects, 18 to 50 years of age
* Demonstrated blanching response to Reference Drug
* Body Mass Index (BMI) of 30 or less
* Good health as determined by lack of clinically significant abnormalities in medical history and clinical assessment, as judged by the Investigator
* Signed and dated informed consent form which meets all criteria of current FDA regulations

Exclusion Criteria

* History of allergy to systemic or topical corticosteroids
* Presence on any skin condition or coloration that would interfere with the placement of test sites or the response or assessment of skin blanching
* Presence of medical condition requiring regular treatment with prescription drugs
* Drug or alcohol addiction requiring treatment in the past 12 months prior to dosing
* Use of any tobacco products in the 30 days prior to study dosing
* Use of any dermatological drug therapy on the flexor surface of the forearms within 30 days of dosing
* Receipt of any drugs as part of a research study within 30 days prior to study dosing
* Pregnant or lactating
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Padagis LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10416918

Identifier Type: -

Identifier Source: org_study_id